In part 2 of this Exclusive Interview, Joel Goldsmith talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the differences between the Freestyle Libre and Pro systems, once of which is patient-focused, the other for clinician monitoring.
Joel Goldsmith is the Senior Director of Digital Platforms at Abbott Diabetes Care where he and his team are focused on designing, developing, and commercializing software-based products and services.
Transcript of this video segment:
Steve Freed – It’s interesting. I was speaking to a number of doctors. I asked almost all of them. I haven’t heard anything bad about CGM. Except for one doctor, who didn’t like your product. I talked to another doctor that loves your product and, you know, somehow this information may help you. The doctor is very well known. I won’t mention his name. He basically said he could never use a blinded program because having the information right in front of you, a patient can see that. Yeah, you can write down what you had a 10 in the afternoon, but people aren’t going to do that. They can actually see the changes and do things according to what’s happening. Then I spoke to a doctor who loves your product because he says you don’t want to give a CGM where people can see the results immediately. Down the road, yes, but in the beginning, I don’t want them to react to anything because people, from his experience, they overreact when they see readings and they forget about onboard insulin. So, it can be very dangerous to just give him a regular CGM where they see the results. This way I can slowly, gradually educate them on the information and then we can switch them over so you get both sides of the same story of why doctors like it or dislike it.
Joel Goldsmith –Yeah, you’re highlighting the defining difference between the Freestyle Libre system that’s intended for use by patients and exposes that information to them whenever they want, wherever they want and Freestyle Libre Pro, that solution that’s designed for clinicians and we very deliberately kept that in a blinded format. And it’s for many of the reasons that you described, but it requires nothing of the patients. So, over the course of a 14-day wear period, they wear that sensor on the back of their upper arm, they don’t have to interact with it at all, there’s nothing to look at or interact with, and therefore they basically forget about it and they lived their daily life like they naturally would. Meanwhile, that sensor is collecting glucose data passively every 15 minutes and at the end of the 14-day wear cycle, all of the data that it’s been captured on that sensor can be downloaded and then analyzed retrospectively through a series of visualization techniques, including their ambulatory glucose profile, which is now part of a standardized glucose report based on a series of guidelines that have been published by AACE and that enables the clinician with the patient to understand the root cause of any issues that they’ve been experiencing and make a faster, informed treatment decision as they change from one treatment regimen to another. So, that was done very deliberately. The other thing that Freestyle Libre Pro system provides is essentially a trial wear experience for the patient. Now even though they didn’t have to interact with that sensor, they now know what it’s like to wear it. So, if they’re a good candidate for the Freestyle Libre system for recurring self-monitoring, now they know exactly what it’s like to wear that sensor so they can make an informed decision.